iFR and FFR are equally safe to diagnose and treat heart disease according to largest-ever analysis of new real-world, long-term data

October 26, 2023

• Safety of Philips’ iFR in the guidance of percutaneous coronary intervention (PCI) for heart disease demonstrated in late-breaking science at TCT 2023 highlighting patient-level outcomes analysis of 42,000 patients from the National Swedeheart Quality Registry
• Previous data demonstrate that iFR delivers consistent patient outcomes, reduces discomfort and offers a more cost-effective and faster diagnostic solution [1,2] compared to FFR

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the latest results demonstrating the safety of Philips instant wave-free ratio (iFR) in the guidance of PCI.

Philips is committed to clinically validating its innovations in cardiac and cardiovascular care. iFR is an innovative pressure-derived index only offered by Philips that is used to assess coronary blockages during interventional procedures. iFR avoids the use of hyperemic agents, a class of drugs that maximize blood flow but have a significant impact on the patient experience [3].

A longitudinal analysis from the National Swedeheart Quality Registry of more than 42,000 patients undergoing coronary procedures, showed no difference between iFR and fractional flow reserve (FFR) in major adverse cardiac events (MACE) [4]. The analysis, “Long-term Safety of Revascularization Deferral Based on Instantaneous Wave-Free Ratio or Fractional Reserve,” compares patient outcomes using iFR and FFR in the diagnosis and treatment of heart disease.

“These new findings once again confirm the safety of iFR. We continue to see that iFR-guided treatment offers consistent outcomes, reduces costs, and provides a better patient experience,” said Dr. Götberg, Department of Cardiology, Clinical Sciences, Lund University, Sweden, who presented the results during a late-breaking science session at the (TCT) annual meeting in San Francisco. “The data from this new analysis provides additional confidence in the safety of iFR for physicians.”

In the previously published analysis of the five-year outcomes of the randomized trial iFR-SWEDEHEART, results found iFR and FFR to be equally safe and effective with respect to risks for MACE. The cumulative MACE risks for each group differentiated by 1.6% (iFR: 21.5%, FFR: 19.9%, HR 1.09 (95% CI: 0.90-1.33 at 5 years). There was no difference in risk for death, heart attack or new revascularization [3].

The results presented today from the SWEDEHEART registry revealed that patients in the iFR group had more risk factors compared with the FFR group but when adjusted for known confounders there was no difference in 5-year MACE between patients who underwent iFR or FFR-guided revascularization (32.2% vs. 31.3%, adjusted HR 0.99, 95%CI 0.93–1.05, p=0.65). Furthermore, the outcome was similar in the individual components of MACE (death, heart attack, new revascularization) as well as in both deferred and treated subgroups.

Patient discomfort can be reduced by 95.7 percent

iFR is considered the Gold Standard for hyperemia-free physiologic assessment for measuring pressure in diagnostic and interventional procedures [1,4]. Similar to FFR, clinicians use these tools coupled with angiographic images to assess coronary blockages. However, by avoiding administrating a hyperemic agent, patient discomfort can be reduced by 95.7 percent and enables iFR to detect disease processes downstream from the major blood vessels [4].

Only Philips iFR has a Class IA recommendation by the American College of Cardiology, American Heart Association, Society for Cardiovascular Angiography & Interventions and European Society of Cardiology [1,2].

“We are confident in our pursuit of innovation to improve outcomes and ensure patient safety. The data continues to demonstrate the benefits of iFR-guided treatment to reduce costs and improve outcomes,” said Chris Landon, General Manager, Philips Image Guided Therapy Devices. “iFR technology is unique to Philips, and we are proud to offer the global gold standard treatment for patients with ischemic heart disease.”

For more information on Philips and the iFR data, please visit  and follow the #TCT2023 conversation with  throughout the event.

[1] Lawton J. et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. JACC. 2022;79(2):e21-e129.

[2] 2018 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European society of cardiology (ESC) and European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2018;00:1-96. Japan guidelines.

[3] Gotberg M, et al. Instantaneous wave-free ratio compared with fractional flow reserve in PCI: A cost-minimization analysis. Int J Cardiol 2021 1;344:54-59.

[4] Gotberg M, Berntorp K, Rylance R, et al. 5 – Year outcomes of PCI guided by measurement of instantaneous wave-free ratio versus fractional flow reserve. J Am Coll Cardiol. 2022;79(10):965–974.

For further information, please contact:

Joost Maltha

Philips Global Press Office

Tel. :

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 70,700 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachments